Most of the salient debate in the literature centers on the benefits/risk ratio of blood component therapy
Despite having multiple guidelines on indications of blood component therapy
in individual derangements, there is no clear-cut evidence regarding benefit from such transfusions and in practice, transfusions also depend on the availability of blood and blood components.
This approach to treatment, referred to as blood component therapy
, allows several patients to benefit from one pint of donated, whole blood.
In developed transfusion centers where component therapy
is the rule, it has been proposed that coagulopathic trauma patients be primarily resuscitated with FFP in a ratio of 1:1:1 to red blood cells and platelets, virtually receiving "reconstituted whole blood.
The Cell Manipulation Core Facility (CMCF) at Dana-Farber Cancer Institute (DFCI) is a manufacturing facility that produces safe and effective novel cellular component therapy
that meets all regulatory guidelines for clinical use and also facilitates research to be translated from the bench to the bedside.
Tahir Shamsi, Consultant Haematologist, NIBD &BMT speaking on Blood Component Therapy
said that Blood transfusion has become very safe during the last two decades.
They recommended that transfusion practices can be improved and made rational by increasing the capacity of the blood bank, by the availability of facilities for component therapy
preparation and storage.
Ultrasound-guided tumour biopsy was performed after aggressive component therapy
to restore platelet level.
Blood component therapy
has many advantages like more efficient utilization of each unit of blood by taking the advantage of differential storage properties of various elements, reduces exposure of patients to unnecessary cellular elements and plasma proteins, minimizes bacterial contamination and eliminates risk of various non-immunogenic reactions like circulatory overload (Turnwald and Pichler, 1985).
Anesthesiologists from North America contribute outlines of assessment, intraoperative and postoperative issues, positioning, monitoring, equipment and procedures, fluid management and blood component therapy
, neuraxial and regional anesthesia, pharmacology, anesthesia and comorbid diseases, and pediatric and subspecialty issues, along with color atlases of regional anesthesia, transesophageal echocardiography, and procedures.
The extinction of 'blood transfusion' in the established economies is now proposed as the way forward for the developing world; the WHO strongly advocates centralised blood centres, component therapy
and fractionation of recovered plasma as the only template (5).
Iftikhar Ahmed, Director Ojha DUHS and Haematological Manifestations and Role of Blood Component Therapy